SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital.
SARS coronavirus
inflammation
pandemics
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
06
04
2021
received:
01
03
2021
accepted:
09
04
2021
pubmed:
11
5
2021
medline:
7
8
2021
entrez:
10
5
2021
Statut:
ppublish
Résumé
The use of Antigen point of care tests (AgPOCT) might be an essential tool to fight the coronavirus disease 2019 (COVID-19) pandemic. Manufacturer information indicates a specificity of about 95% and there is a growing interest to use these tests area-wide. Therefore, it is necessary to clarify whether AgPOCT can be used safely for "rule-in" (detection of positive patients) and for "rule-out" (valid negative testing). Two thousand three hundred and seventy-five patients received polymerase chain reaction (PCR) testing and AgPOCT for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of symptoms. The positive predictive value of symptomatic and asymptomatic patients was compared with a cut-off threshold cycle (C
Identifiants
pubmed: 33969499
doi: 10.1002/jmv.27033
pmc: PMC8242658
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5323-5327Informations de copyright
© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.
Références
J Med Virol. 2021 Sep;93(9):5323-5327
pubmed: 33969499
PLoS One. 2021 Mar 31;16(3):e0248921
pubmed: 33788882
Biomarkers. 2021 May;26(3):213-220
pubmed: 33455451
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252